Tranexamic Acid Tablets (Lysteda)

Elliott, William T.; Chan, James
January 2010
Internal Medicine Alert;1/29/2010, Vol. 32 Issue 2, p14
Product Review
The article evaluates the antifibrinolytic drug Tranexamic Acid tablets from Xanodyne Pharmaceuticals Inc.


Related Articles

  • Xanodyne Pulls Darvon, Darvocet From Market.  // Chain Drug Review;12/6/2010, Vol. 32 Issue 21, p92 

    The article reports on the withdrawal of branded versions of the prescription pain medication propoxyphene, Darvon and Darvocet, by Xanodyne Pharmaceuticals Inc. from the U.S. market at the request of the Food and Drug Administration.

  • Mallinckrodt signs agreement with Xanodyne for opioid analgesic.  // PharmaWatch: CNS;Oct2012, Vol. 11 Issue 10, p17 

    The article reports that Mallinckrodt, the pharmaceuticals unit of Covidien and a supplier of opioid pain drugs, has inked a deal with Xanodyne Pharmaceuticals to buy Roxicodone, or oxycodone hydrochloride tablets USP, in 5, 15, and 30mg dosage strengths.

  • JALYN.  // MPR - Pharmacist's Edition;Winter2010/2011, Vol. 4 Issue 4, pA.5 

    The article evaluates the enzyme inhibitor Jalyn from GlaxoSmithKline.

  • Tranexamic Acid Tablets. Cada, Dennis J.; Levien, Terri L.; Baker, Danial E. // Hospital Pharmacy;May2010, Vol. 45 Issue 5, p393 

    The article provides information on Lysteda or tranexamic acid tablets from Xanodyne, indicated for the treatment of cyclic heavy menstrual bleeding. The drug is a synthetic lysine amino acid derivative antifibrinolytic and has been available over-the-counter (OTC) in Sweden for over 10 years....

  • Financings Roundup.  // BioWorld Today;11/13/2007, Vol. 18 Issue 221, p4 

    The article provides information on Xanodyne Pharmaceuticals Inc., a pharmaceutical company in Newport, Kentucky. It was reported that Xanodyne filed for an initial public offering as of November 13, 2007. The pharmaceutical company did not disclosed the targeted number of shares or its price...

  • Propoxyphene withdrawn.  // MPR - Urologists' Edition;Fall2010/Winter2011, Vol. 7 Issue 1, pA6 

    The article reports on the announcement by the U.S. Food and Drug Administration that Xanodyne Pharmaceuticals Inc. has withdrawn its propoxyphene in the U.S. market due to information that the drug can cause cardiotoxicity.

  • Financings Roundup.  // BioWorld Today;6/5/2009, Vol. 20 Issue 107, p5 

    The article reports on the $38 million secured by Xanodyne Pharmaceuticals Inc. from an equity financing. According to the company, the financing, which was led by MPM Capital, will be used to launch two assets in the U.S., namely Zipsor for acute pain and XPI2B for heavy menstrual bleeding.

  • Dextropropoxyphene products withdrawn from US market.  // Reactions Weekly;11/27/2010, Issue 1329, p5 

    The article reports that Xanodyne Pharmaceuticals has withdrawn its dextropropoxyphene products from the market as requested by the U.S. Food and Drug Administration (FDA).

  • Other News To Note.  // BioWorld Today;11/22/2010, Vol. 21 Issue 226, p6 

    This section offers news briefs on the biotechnology industry, including stock split done by Ligand Pharmaceuticals Inc., the failure of Marshall Edwards Inc. to comply with Nasdaq's minimum 10 million dollar stockholders' equity requirement and the decision of Xanodyne Pharmaceuticals Inc. to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics